Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's TMC435 Joins The Pharmasset Club

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharmasset and J&J's Tibotec unit will initiate a Phase II study evaluating the combination of the investigational nucleotide polymerase inhibitor PSI-7977 and protease inhibitor TMC435.

You may also be interested in...



Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset

The planned purchase price of $11 billion, or $137 a share, an 89% premium over Pharmasset’s closing price on Nov. 18, is by far the highest ever paid for a clinical-stage biotech.

Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm

With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.

Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm

With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel